Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

NCT03991884 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Recurrent B Acute Lymphoblastic Leukemia
Recurrent B Lymphoblastic Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Refractory B Lymphoblastic Lymphoma

Interventions

DRUG: Etoposide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: Cyclophosphamide
BIOLOGICAL: Inotuzumab Ozogamicin

Sponsor

University of Washington

Collaborators

[object Object]